Grünenthal Reports Strong Financial Results for 2025

Grünenthal, a prominent player in pain management, reported solid financial results for 2025. The company achieved stable revenue of €1.8 billion, with a record-high adjusted EBITDA of €500 million. This growth was largely thanks to the increased sales of Qutenza® and Movantik® as well as strategic acquisitions.

Operating cash flow saw a 46% rise, reaching €309 million. Grünenthal ended the year with a net leverage of 2.24x and issued a €175 million bond extension to boost its liquidity for future investments.

Progress was made in their innovation pipeline, with the advancement of tegacorat (GRM) and NOP programmes into subsequent clinical development phases. Additionally, Grünenthal's strategic acquisitions, including Cialis® and PecFent®, expanded their portfolio.

The company maintained its robust financial position while enhancing its global operations, including gaining EU regulatory approval for its production site in Ecuador.